Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Public ClinicalTrials.gov record NCT06097832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Study identification
- NCT ID
- NCT06097832
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2024 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Jan 2039 (Estimated)
- Last update posted
- Jul 14, 2026
2024 – 2039
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sutter Health Alta Bates | Berkeley | California | 94704 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| Stanford University | Stanford | California | 94305 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| The University of Kansas Cancer Center | Fairway | Kansas | 66205 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Comprehensive Cancer Center | New York | New York | 10065 | — |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45267 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Baptist Memorial Hospital | Memphis | Tennessee | 381202127 | — |
| Huntsman Cancer Institute at the University of Utah | Salt Lake City | Utah | 84112 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06097832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06097832 live on ClinicalTrials.gov.